Novartis Nabs FDA Nod for Rare Disease Drug Rival to AstraZeneca Meds

FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two infused AstraZeneca drugs, Novartis’s pill is well-positioned to take market share from those blockbuster products.

Related Keywords

United States ,San Diego ,California ,American ,Astrazeneca Soliris ,Novartis Fabhalta ,American Society Of Hematology ,Novartis ,Apellis Pharmaceuticals ,Astrazeneca ,American Society ,Risk Evaluation ,Mitigation Strategy ,Weight Loss ,Obesity ,Verweight ,Diabetes ,Massachusetts ,Medical Devices ,Startups ,Healthcare Innovation ,Medcity News ,San Francisco ,Life Sciences ,Accelerator ,Rock Health ,Startup Advice ,Startup Funding ,Patient Monitoring System ,Otion Sensors ,Dc ,Healthcare It ,Washington ,Foodborne Pathogens ,Iagnostics Company ,Iagnostic Platforms ,Minimally Invasive Surgery ,Aser Surgery ,Cambridge ,Dealflow ,Hospitals ,Wellpoint ,Ealthways ,Ealth And Wellness ,Mployee Wellness Programs ,Investing ,Wellness ,Medtronic ,Hanghai Innovation Center ,China ,R D ,Mdt ,Minneapolis ,Minnesota ,Publics ,Twin Cities ,Ulcerative Colitis ,Abbott Labs ,Humira ,Doctors ,Pharmaceuticals ,Skin Disorders ,D Anderson Cancer Center ,Cancer ,Texas ,Renal Denervation ,St Jude Medical ,Stj ,Emr ,Hr ,Electronic Health Records ,Electronic Medical Records ,Certified Emr ,Ehr ,Advanced Cellular Technology ,Amyotrophic Lateral Sclerosis ,Embryonic Stem Cells ,Geron Corporation ,Lou Gehrigs Disease ,Macular Degeneration ,Regenerative Medicine ,Spinal Cord Damage ,Value Based Healthcare System ,Obamacare ,Ee For Service Model ,Cleveland ,Health Insurance ,Insurance ,Ohio ,Pennsylvania ,Politics ,Cancer Treatment Options Library ,Aetna ,Pet ,Aet ,Health It ,Phi ,Philadelphia ,Clinical Trials ,Complement System ,Fabhalta ,Fda ,Rare Disease , ,